IP Library Granted Patent US 10,092,608
Granted Patent B2
US 10,092,608 · App. 14/948,730 · Granted Oct 9, 2018

Reducing conjugative plasmids in bacteria

Inventors: C. B. Appaiah (Bangalore, IN); Jayasheela Manur (Bangalore, IN); Bharathi Sriram (Bangalore, IN)
Assignee: GangaGen, Inc.
A61K35/76A01N63/00C07K14/005C12N1/20C12N15/74
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,092,608
App. No.
14/948,730
Granted
Oct 9, 2018
Kind
B2
Abstract

The present invention provides methods and compositions to reduce prevalence of plasmids in microbial colonies, including infections, and includes therapeutic compositions, methods for treatment of infections, and methods for identifying additional such compositions. Means are provided to reduce the copy numbers of antibiotic resistance genes, and to confer phage binding to cells lacking receptors for those phage.

Claims (15)

1. A method for reducing the number of a recipient bacterial population comprising the steps of:

(a) transferring a conjugative plasmid from a donor bacterial population to the recipient bacterial population, wherein the conjugative plasmid is selected from the group consisting of Inc group N, P, W, D, M, X, P1, U, C, or J; wherein the transferring comprises contacting the donor bacterial population with the recipient bacterial population, and wherein the recipient bacterial population is not susceptible to binding by a phage until the recipient bacterial population expresses a phage receptor expressed by the conjugative plasmid; and

(b) contacting the recipient bacterial population with the phage that binds to the phage receptor, wherein said contacting localizes the phage to recipient bacteria expressing the phage receptor,

thereby reducing the number of the recipient bacterial population.

2. The method of claim 1 , wherein the plasmid comprises a recombinant expression cassette comprising a strong promoter functional in the recipient bacterial population operably linked to a sequence encoding the phage receptor.

3. The method of claim 1 , wherein the plasmid is selected from the group consisting of:

Inc group N, P, and W.

4. The method of claim 1 , wherein the phage is selected from the group consisting of Tectiviridae, Inoviridae, Leviviridae, Siphoviridae, filamentous phage, and RNA phage.

5. The method of claim 1 , wherein the conjugative plasmid is modified.

6. The method of claim 1 , wherein the donor bacterial population comprises bacteria from at least one genus selected from the group consisting of:

Escherichia, Pseudomonas, Salmonella, Proteus, Vibrio, Acinetobacter, Bacillus , and Micrococcus.

7. The method of claim 1 , wherein the recipient bacterial population comprises bacteria from at least one genus selected from the group consisting of:

Escherichia, Pseudomonas, Salmonella, Proteus, Vibrio, Acinetobacter, Bacillus , and Micrococcus.

8. The method of claim 1 , wherein the method is carried out in vitro.

9. The method of claim 1 , wherein the recipient bacterial population is killed by the phage.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2020
From: GANGAGEN, INC.
To: BACTOCLEAR HOLDINGS PTE. LTD.
Reel/Frame 052603/0390 →
RELEASE OF SECURITY INTEREST Recorded Jan 14, 2020
From: ATEL VENTURES, INC.
To: GANGAGEN, INC.
Reel/Frame 051507/0381 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2020
From: GANGAGEN, INC.
To: BACTOCLEAR HOLDINGS PTE. LTD.
Reel/Frame 051499/0244 →
SECURITY INTEREST Recorded Jul 26, 2018
From: GANGAGEN, INC.
To: ATEL VENTURES, INC.
Reel/Frame 046475/0531 →
Continuity (3)
Continuation 12922114
Provisional Application 61035304 · Mar 10, 2008
Related Publication 20160310549A1 · Oct 27, 2016